Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: Results of the UNICANCER ACCORD 16 phase II trial

Annals of Oncology

Volumn 24, Issue 11, 2013, Pages 2834-2838

  Deutsch, E ^a   Lemanski, C ^b   Pignon, J P ^a   Levy, A ^a   Delarochefordiere, A ^c   Martel Lafay, I ^d   Rio, E ^e   Malka, D ^f   Conroy, T ^a   Miglianico, L ^g   Becouarn, Y ^h   Malekzadeh, K ^a   Paris, E ^a   Juzyna, B ⁱ   Ezra, P ^a   Azria, D ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE VAL D AURELLE   (France)

^c INSTITUT CURIE   (France)

^d CENTRE LÉON BÉRARD   (France)

^e UMR INSERM U892 CNRS 6299   (France)

^f CENTRE ALEXIS VAUTRIN   (France)

^g Centre Hospitalier Privé Saint Grégoire Rennes   (France)

^h INSTITUT BERGONIÉ   (France)

ⁱ UNICANCER   (France)

Author keywords

Anal cancer; Cetuximab; Chemoradiotherapy; Phase II; Targeted therapy; Toxicity

Indexed keywords

CETUXIMAB; CISPLATIN; FLUOROURACIL;

ABDOMINAL PAIN; ACNE; ADULT; ADVANCED CANCER; ANITIS; ANUS CARCINOMA; ANUS DISEASE; ARTICLE; BRACHYTHERAPY; CHEMORADIOTHERAPY; CHRONIC PAIN; CLINICAL ARTICLE; COLOSTOMY; CONTINUOUS INFUSION; DRUG DOSE REDUCTION; DRUG FATALITY; EXTERNAL BEAM RADIOTHERAPY; FEVER; FISTULA; FOLLOW UP; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HUMAN; INFECTION; INTENSITY MODULATED RADIATION THERAPY; KIDNEY FAILURE; LOADING DRUG DOSE; LOCALLY ADVANCED ANAL CANAL CARCINOMA; LOW BACK PAIN; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NECROSIS; OVERALL SURVIVAL; PATIENT COMPLIANCE; PERINEAL FISTULA; PERINEAL NECROSIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROCTITIS; PROGRESSION FREE SURVIVAL; RADIATION DOSE REDUCTION; SKIN DISEASE;

ANAL CANCER; CETUXIMAB; CHEMORADIOTHERAPY; PHASE II; TARGETED THERAPY; TOXICITY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANUS NEOPLASMS; CHEMORADIOTHERAPY; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY;

EID: 84887095202     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt368     Document Type: Article

References (24)

1. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research Lancet. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet 1996; 348: 1049-1054.
2. Flam M, John M, Pajak TF et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996; 14: 2527-2539.
3. Bartelink H, Roelofsen F, Eschwege F et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997; 15: 2040-2049.
4. Touboul E, Schlienger M, Buffat L et al. Epidermoid carcinoma of the anal canal. Results of curative-intent radiation therapy in a series of 270 patients. Cancer 1994; 73: 1569-1579.
5. Meropol NJ, Niedzwiecki D, Shank B et al. Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281). J Clin Oncol 2008; 26: 3229-3234.
6. Peiffert D, Tournier-Rangeard L, Gérard JP et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 Trial. J Clin Oncol 2012; 30: 1941-1948.
7. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59: 1935-1940.
8. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamouscell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
9. Govindan R, Bogart J, Stinchcombe T et al. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B Trial 30407. J Clin Oncol 2011; 29: 3120-3125.
10. Blumenschein GR, Jr, Paulus R, Curran WJ et al. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol 2011; 29: 2312-2318.
11. Ruhstaller T, Pless M, Dietrich D et al. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II trial (SAKK 75/06). J Clin Oncol 2011; 29: 626-631.
12. Crane CH, Varadhachary GR, Yordy JS et al. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4 (Dpc4) immunostaining with pattern of disease progression. J Clin Oncol 2011; 29: 3037-3043.
13. Paliga A, Onerheim R, Gologan A et al. EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors? Br J Cancer 2012; 107: 1864-1868.
14. Olivatto LO, Meton F, Bezerra M et al. Phase I study of cetuximab in combination with 5-fluorouraci, cisplatin, and radiotherapy in patients with locally advanced squamous cell anal carcinoma (abstr. #4609). J Clin Oncol 2008; 26: 15S.
15. Vieillot S, Fenoglietto P, Lemanski C et al. IMRT for locally advanced anal cancer: clinical experience of the Montpellier Cancer Center. Radiat Oncol 2012; 7: 45.
16. Garg M, Lee JY, Kachnic LA et al. Phase II trials of cetuximab plus cisplatin, 5-fluorouracil and radiation in immunocompetent (ECOG 3205) and HIV-positive (AMC045) patients with squamous cell carcinoma of the anal canal: safety and preliminary efficacy results (abstr. #4030). J Clin Oncol 2012; 30: 15S.
17. Doyen J, Benezery K, Ortholan C et al. Predictive factors of early and late local toxicities in anal cancer treated by radiotherapy in combination with or without chemotherapy (abstr. #667). J Clin Oncol 2012; 30: 15S.
18. Kachnic LA, Tsai HK, Coen JJ et al. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy. Int J Radiat Oncol Biol Phys 2012; 82: 153-158.
19. Salama JK, Mell LK, Schomas DA et al. Concurrent chemotherapy and intensitymodulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol 2007; 25: 4581-4586.
20. Bazan JG, Hara W, Hsu A et al. Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Cancer 2011; 117: 3342-3351.
21. Olivatto LO, Cabral V, Rosa A et al. Mitomycin-C- or cisplatin-based chemoradiotherapy for anal canal carcinoma: long-term results. Int J Radiat Oncol Biol Phys 2011; 79: 490-495.
22. Gunderson LL, Winter KA, Ajani JA et al. Long-term update of US GI Intergroup RTOG 98-11 Phase III Trial for Anal Carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol 2012; 30: 4344-4351.
23. James RD, Glynne-Jones R, Meadows HM et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial. Lancet Oncol 2013; 14: 516.
24. Peiffert D, Seitz JF, Rougier P et al. Preliminary results of a phase II study of highdose radiation therapy and neoadjuvant plus concomitant 5-fluorouracil with CDDP chemotherapy for patients with anal canal cancer: a French cooperative study. Ann Oncol 1997; 8: 575.